- Entry
- $19.34
- Now
- $24.50 +26.7%
- Target
- $35.00
- Score
- —
1. Lumvoa won total approval for both active and chronic Thyroid Eye Disease. 2. Cuts Tepezza treatment in half 3. phase three trials demolished placebo 4. $1.1b liquid for launch 5. Pricing target estimate $35
— ORIGINAL POST ·
VRDN
· r/smallstreetbets
· Jun 29, 2026